免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌研究进展

Research advances in immune checkpoint inhibitors in the treatment of metastatic castration-resistant prostate cancer

免疫检查点抑制剂(ICIs)能够解除免疫抑制,恢复和增加免疫细胞对肿瘤细胞的杀伤力,改善了多种晚期实体肿瘤患者的预后。研究显示,ICIs治疗转移性去势抵抗性前列腺癌(mCRPC)整体有效率较低,但对存在微卫星高不稳定性(MSI-H)、DNA错配修复功能缺陷(dMMR)、高肿瘤突变负荷(TMB)等患者的疗效可观。本文回顾了近年来ICIs单药或联合应用于mCRPC的研究进展,并总结了预测ICIs疗效的生物标志物,期望能够为ICIs的临床应用和学术研究提供有益信息。

Immune checkpoint inhibitors(ICIs)can release immunosuppression,restore and increase the lethality of immune cells to tumor cells,thus improve the prognosis of patients with several advanced solid tumors.Studies have shown that ICIs are less effective in the treatment of metastatic castration-resistant prostate cancer(mCRPC),but are effective in patients with microsatellite instability-high(MSI-H),DNA mismatch repair function defects(dMMR),and high tumor mutation burden(TMB).This review focuses on the apply of ICIs or combined therapy on mCRPC,and summarizes the biomarkers that predict the efficacy of ICIs.